Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

By Yuhui Huang, Jianping Yuan, E. Righi, W. Kamoun, M. Ancukiewicz, Jean Nézivar, Michael Santosuosso, John D. Martin, Margaret R. Martin, F. Vianello and 7 more. Proceedings of the National Academy of Sciences of the United States of America, 2012

1,011 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/060d15dda8915651bc8e6c6c06e3234cc5fce574

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Oliver Kepp
5. A. Buqué
6. Rakesh K. Jain
7. M. Smyth
8. V. Schirrmacher

In Molecular Biology

1. Guido Kroemer
2. L. Galluzzi
3. Triantafyllos Stylianopoulos
4. John D. Martin
5. L. Zitvogel
6. Oliver Kepp
7. B. Larrivée
8. C. Viallard

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. Triantafyllos Stylianopoulos
4. L. Zitvogel
5. John D. Martin
6. Rakesh K. Jain
7. Oliver Kepp
8. B. Larrivée

Citations in the corpus

• Vascular normalization as an emerging strategy to enhance cancer immunotherapy (2013, neutral): “Furthermore, TAMs in perfused regions of tumors express lower levels of M2-like genes, including Arg1, CSF-1, TGF-b, and matrix metalloproteinase (MMP)-9, than TAMs distant from functional blood vessels (8).”
• Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. (2013, background): “ment of tumors into an immunostimulatory one, presumably by alleviating hypoxia (Fig 4B).(104,111-116) With the recent approval of a number of immunotherapeutics for cancer and many more in clinical”
• Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, background): “As prolonged maintenance of vascular normalization would be required to enhance the therapeutic index of chemotherapy, radiotherapy and particularly immunotherapies, it becomes essential to develop strategies leading to efficient and long-term stabilization of tumor blood vessels [108].”
• The role of mechanical forces in tumor growth and therapy (2014, positive): “A | Intravital multiphoton microscopy images show treatment with the angiotensin receptor blocker, losartan lowers collagen levels (blue) and increases the density of perfused vessels (green) in an orthotopic mammary adenocarcinoma (EO771) [Reproduced from Reference (135)].”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…doses of a mAb specific for the VEGF receptor kinase insert domain receptor (KDR) not only promote the normalization of the tumor vasculature, but also favor the depletion of MDSCs and the reprogramming of tumor-associated macrophages toward an immunostimulatory phenotype (Huang et al., 2012).”
• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “Huang et al. also discover that in mouse breast cancer models, using a low dose of vascular normalization agent, anti-VEGFR2 antibodies, can increase CD4 + and CD8 + T cell infiltration, reprogram the tumor microenvironment, and enhance the efficacy of immunotherapy [384].”